{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T03:13:59Z","timestamp":1780542839984,"version":"3.54.1"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n                  <jats:p>\n                    Cutaneous metastases of breast neoplasms indicate advanced disease with poor prognosis. The role of Preferentially Expressed Antigen in Melanoma (PRAME) expression in breast cancer skin metastases remains poorly understood. In this study, we investigate PRAME expression in breast carcinoma metastatic to the skin, particularly triple-negative breast cancers (TNBC). A retrospective review of breast cancer cases with skin metastasis was conducted from January 2005 to March 2023. PRAME immunostaining was performed on skin metastatic lesions and corresponding primary tumors. A comparison group of noncutaneous metastases (n = 11) was included. Thirty patients with cutaneous metastasis were identified (29 women, 1 man; mean age 63 years). The most common site of skin metastasis was chest (25 cases, 83%). Histologically, 25 cases (83%) were invasive ductal carcinoma. Eleven cases (37%) were TNBC. PRAME positivity was observed in 10 skin metastases (33%) with 70% being triple negative. Among 20 available primary samples, only 3 were PRAME positive with corresponding positive metastases. Comparison group showed minimal PRAME expression. In total, 40% of patients died, with TNBC associated with higher mortality (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = 0.04). All PRAME-positive TNBC patients with follow-up were deceased. In conclusion, PRAME expression occurred in approximately one-third of breast cancer skin metastases, with predominance in triple-negative breast cancer. These findings warrant further investigation of PRAME's role in cutaneous metastasis and its diagnostic implications.\n                  <\/jats:p>","DOI":"10.1097\/dad.0000000000003159","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T15:00:23Z","timestamp":1760713223000},"page":"107-113","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Evaluation of PRAME Expression in Cases of Breast Carcinoma Metastatic to Skin"],"prefix":"10.1097","volume":"48","author":[{"given":"Rachel C.","family":"Chang","sequence":"first","affiliation":[{"name":"Rush Medical College, Rush University Medical Center, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vida","family":"Ehyaee","sequence":"additional","affiliation":[{"name":"Department of Pathology, Rush University Medical Center, Chicago, IL; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafat","family":"Wattar","sequence":"additional","affiliation":[{"name":"Department of Pathology, Rush University Medical Center, Chicago, IL; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankica","family":"Braun","sequence":"additional","affiliation":[{"name":"Department of Pathology, Rush University Medical Center, Chicago, IL; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gattuso","sequence":"additional","affiliation":[{"name":"Department of Pathology, Rush University Medical Center, Chicago, IL; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aadil","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department of Pathology, Rush University Medical Center, Chicago, IL; and"},{"name":"Director of Dermatopathology, Illinois Dermatology Institute, Park Ridge, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"R1-20260127","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1188\/02.CJON.255-260","article-title":"Cutaneous metastatic breast cancer","volume":"6","author":"Moore","year":"2002","journal-title":"Clin J Oncol Nurs"},{"key":"R2-20260127","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/jso.26870","article-title":"Cutaneous metastasectomy: is there a role in breast cancer? A systematic review and overview of current treatment modalities","volume":"126","author":"Huang","year":"2022","journal-title":"J Surg Oncol"},{"issue":"suppl 1","key":"R3-20260127","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1186\/1471-2482-12-S1-S6","article-title":"Electrochemotherapy of cutaneous metastastes from breast cancer in elderly patients: a preliminary report","volume":"12","author":"Benevento","year":"2012","journal-title":"BMC Surg"},{"key":"R4-20260127","first-page":"90","article-title":"Cutaneous metastasis from breast carcinoma: a brief report of a rare variant and proposed morphological classification","volume":"1","author":"Chisti","year":"2013","journal-title":"Gulf J Oncolog"},{"key":"R5-20260127","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1001\/archderm.143.5.613","article-title":"Clinicopathologic correlation of cutaneous metastases: experience from a cancer center","volume":"143","author":"Sariya","year":"2007","journal-title":"Arch Dermatol"},{"key":"R6-20260127","doi-asserted-by":"crossref","first-page":"793937","DOI":"10.1155\/2014\/793937","article-title":"A clinicopathological and immunohistochemical correlation in cutaneous metastases from internal malignancies: a five-year study","volume":"2014","author":"Nibhoria","year":"2014","journal-title":"J Skin Cancer"},{"key":"R7-20260127","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.0303-6987.2004.00207.x","article-title":"Cutaneous metastasis: a clinical, pathological, and immunohistochemical appraisal","volume":"31","author":"Saeed","year":"2004","journal-title":"J Cutan Pathol"},{"key":"R8-20260127","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/j.1600-0560.2009.01469.x","article-title":"Skin metastasis: a pathologist's perspective","volume":"37","author":"Hussein","year":"2010","journal-title":"J Cutan Pathol"},{"key":"R9-20260127","first-page":"e20301","article-title":"Pleomorphic appearance of breast cancer cutaneous metastases","volume":"13","author":"Cohen","year":"2021","journal-title":"Cureus"},{"key":"R10-20260127","first-page":"001356","article-title":"A first sign not to be missed: cutaneous metastasis from breast cancer","volume":"7","author":"Ara\u00fajo","year":"2020","journal-title":"Eur J Case Rep Intern Med"},{"key":"R11-20260127","doi-asserted-by":"crossref","first-page":"e26737","DOI":"10.1097\/MD.0000000000026737","article-title":"Retrospective review of cutaneous metastasis among 11,418 patients with solid malignancy: a tertiary cancer center experience","volume":"100","author":"Teyateeti","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"R12-20260127","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/sj.bjc.6604494","article-title":"PRAME expression and clinical outcome of breast cancer","volume":"99","author":"Epping","year":"2008","journal-title":"Br J Cancer"},{"key":"R13-20260127","doi-asserted-by":"crossref","first-page":"e12770","DOI":"10.1111\/cpr.12770","article-title":"The role of the cancer testis antigen PRAME in tumorigenesis and immunotherapy in human cancer","volume":"53","author":"Xu","year":"2020","journal-title":"Cell Prolif"},{"key":"R14-20260127","doi-asserted-by":"crossref","first-page":"8828579","DOI":"10.1155\/2020\/8828579","article-title":"Clinicopathological and prognostic significance of PRAME overexpression in human cancer: a meta-analysis","volume":"2020","author":"Li","year":"2020","journal-title":"Biomed Res Int"},{"key":"R15-20260127","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1182\/bloodadvances.2022008304","article-title":"Therapeutic targeting of PRAME with mTCRCAR T cells in acute myeloid leukemia","volume":"7","author":"Kirkey","year":"2023","journal-title":"Blood Adv"},{"issue":"16_suppl","key":"R16-20260127","doi-asserted-by":"crossref","first-page":"9507","DOI":"10.1200\/JCO.2024.42.16_suppl.9507","article-title":"Phase 1 safety and efficacy of IMC-F106C, a PRAME \u00d7 CD3 ImmTAC bispecific, in post-checkpoint cutaneous melanoma (CM)","volume":"42","author":"Hamid","year":"2024","journal-title":"J Clin Oncol"},{"key":"R17-20260127","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1097\/PAS.0000000000001134","article-title":"PRAME expression in melanocytic tumors","volume":"42","author":"Lezcano","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"R18-20260127","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1097\/DAD.0000000000001885","article-title":"Preferentially expressed antigen in melanoma immunostaining in a series of melanocytic neoplasms","volume":"43","author":"Googe","year":"2021","journal-title":"Am J Dermatopathol"},{"key":"R19-20260127","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/DAD.0000000000002440","article-title":"Immunohistochemistry for PRAME in dermatopathology","volume":"45","author":"Lezcano","year":"2023","journal-title":"Am J Dermatopathol"},{"key":"R20-20260127","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/DAD.0000000000002501","article-title":"A comparison of preferentially expressed antigen in melanoma immunohistochemistry and diagnostic gene expression-profiling assay in challenging melanocytic proliferations","volume":"46","author":"Casillas","year":"2024","journal-title":"Am J Dermatopathol"},{"key":"R21-20260127","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1097\/PAS.0000000000001944","article-title":"PRAME expression in cancer: a systematic immunohistochemical study of >5800 epithelial and nonepithelial tumors","volume":"46","author":"Kaczorowski","year":"2022","journal-title":"Am J Surg Pathol"},{"key":"R22-20260127","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.path.2021.01.001","article-title":"PRAME immunohistochemistry as an ancillary test for the assessment of melanocytic lesions","volume":"14","author":"Lezcano","year":"2021","journal-title":"Surg Pathol Clin"},{"issue":"suppl 2","key":"R23-20260127","doi-asserted-by":"crossref","first-page":"A299","DOI":"10.1093\/ajcp\/144.suppl2.299","article-title":"SOX10 is a useful marker for triple negative breast cancer","volume":"144","author":"Peevey","year":"2015","journal-title":"Am J Clin Pathol"},{"key":"R24-20260127","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.cell.2005.07.003","article-title":"The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling","volume":"122","author":"Epping","year":"2005","journal-title":"Cell"},{"key":"R25-20260127","doi-asserted-by":"crossref","first-page":"154299","DOI":"10.1016\/j.prp.2022.154299","article-title":"The role of PRAME and NY-ESO-1 as potential therapeutic and prognostic biomarkers in triple-negative breast carcinomas","volume":"241","author":"See","year":"2023","journal-title":"Pathol Res Pract"},{"key":"R26-20260127","doi-asserted-by":"crossref","first-page":"10376","DOI":"10.1111\/jcmm.16967","article-title":"Cancer testis antigen PRAME: an anti-cancer target with immunomodulatory potential","volume":"25","author":"Naik","year":"2021","journal-title":"J Cell Mol Med"},{"key":"R27-20260127","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.breast.2018.08.106","article-title":"Expression of NY-ESO-1, MAGE-A3, PRAME and WT1 in different subgroups of breast cancer: an indication to immunotherapy?","volume":"42","author":"Tessari","year":"2018","journal-title":"Breast"},{"key":"R28-20260127","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.breast.2019.12.002","article-title":"Expression of tumor-associated antigens in breast cancer subtypes","volume":"49","author":"Curigliano","year":"2020","journal-title":"Breast"},{"key":"R29-20260127","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10549-007-9643-3","article-title":"Prevalence and prognostic and predictive relevance of PRAME in breast cancer","volume":"109","author":"Doolan","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"R30-20260127","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12967-018-1757-3","article-title":"PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer","volume":"17","author":"Al-Khadairi","year":"2019","journal-title":"J Transl Med"}],"container-title":["The American Journal of Dermatopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DAD.0000000000003159","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T22:00:30Z","timestamp":1769551230000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DAD.0000000000003159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/dad.0000000000003159","relation":{},"ISSN":["0193-1091","1533-0311"],"issn-type":[{"value":"0193-1091","type":"print"},{"value":"1533-0311","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]}}}